Zaiqi Wang, M.D., Ph.D.
Chairman & Chief Executive Officer
Zaiqi Wang has served as our chairman and CEO since November 2018.Prior to
this, Dr. Zaiqi Wang served as GM, Roche China Innovation Center from 2017 to
Nov 2018 where he managed 140 scientists and over 10 programs from
discovery to early development. From 2011 to 2017, Dr. Zaiqi Wang served as
Vice President at MSD China Development Center during which time he was
responsible for all China clinical programs; key driver for NDA approval of
Keytruda, Gardasil, Zepatir, Rotateq, Noxafil, Emend, Orgalutran and Bridion in
China and led the overall Keytruda China development strategy, especially by
driving melanoma as the leading indication. From 2001 to 2010, Dr. Zaiqi Wang
was served as Director of Early Clinical Research and Experimental Medicine at
Schering Plough where he was responsible for 7 FIH programs, and built up the
translational research unit in Singapore, Chaired VLA-4 early development
program and served as chair for protocol review committee for 2 years.
Previously he was served as Assistant Clinical Pharmacologist, Phase 1 Unit at Eli
Lilly from June 2001 to Dec 2001. Dr. Zaiqi Wang is Internist with board-certified
Clinical Pharmacology in US and he received PhD in Biochemistry from Virginia
Tech and pursued his Postdoc in John Hopkins University.